Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAGVXW)

Drug Name
KENPAULLONE Drug Info
Synonyms
kenpaullone; 142273-20-9; 9-Bromopaullone; NSC 664704; 9-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; NSC-664704; NSC664704; MLS002702152; CHEMBL296586; 9-Bromo-7,12-dihydroindolo(3,2-d)(1)benzazepin-6(5H)-one; Indolo[3,2-d][1]benzazepin-6(5H)-one,9-bromo-7,12-dihydro-; QQUXFYAWXPMDOE-UHFFFAOYSA-N; 9-Bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one; 9-bromo-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Bromo-7,12-dihydro-indolo-[3,2-d]-[1]benzazepin-6(5H)-one
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
3820
ChEBI ID
CHEMBL296586
CAS Number
CAS 142273-20-9
TTD Drug ID
DMAGVXW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Investigative Drug(s)
Patented Agent(s)
Preclinical Drug(s)
Discontinued Drug(s)
Clinical Trial Drug(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Plasmodium CDK Pfmrk (Malaria Pfmrk)
Drug Name Drug ID Indication ICD 11 Highest Status REF
APIGENIN DMI3491 Discovery agent N.A. Investigative [5]
2,5-dichloro-N-p-tolylthiophene-3-sulfonamide DMU5J8Y Discovery agent N.A. Investigative [10]
WR-289010 DMS2QUL Discovery agent N.A. Investigative [11]
WR-080539 DMUCGK8 Discovery agent N.A. Investigative [11]
5-chloro-4-nitrothiophene-2-sulfonamide DMRS82Q Discovery agent N.A. Investigative [10]
Oxindole derivative DM1AU8V Malaria 1F40-1F45 Investigative [12]
WR-203581 DM9M1UO Discovery agent N.A. Investigative [11]
WR-289009 DM5W9GR Discovery agent N.A. Investigative [11]
N-(2-aminoethyl)isoquinoline-5-sulfonamide DMG2MSX Discovery agent N.A. Investigative [13]
2-chloro-N-(o-tolylcarbamoyl)benzamide DMLDQ6I Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cyclin-dependent kinase 5 (CDK5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Roscovitine derivative 1 DMD1G3Z N. A. N. A. Patented [14]
Tricyclic benzimidazole derivative 1 DM5SD9E N. A. N. A. Patented [14]
4-(thiazol-5-yl)-pyrimidine derivative 2 DMMQFCN N. A. N. A. Patented [14]
Pyrazolo[1,5-a]-1,3,5-triazine derivative 1 DMOK7CW N. A. N. A. Patented [14]
Naphthyridine and isoquinoline derivative 1 DMTGIP7 N. A. N. A. Patented [14]
PMID26161698-Compound-18 DM6JVR5 N. A. N. A. Patented [14]
Flavonoid derivative 7 DM6A9UR N. A. N. A. Patented [14]
L-751250 DMOERXK Obesity 5B81 Preclinical [15]
Olomoucine DMNAFG1 N. A. N. A. Terminated [15]
aloisine A DM5U1LN Discovery agent N.A. Investigative [16]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cyclin-dependent kinase 1 (CDK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
R-roscovitine DMSH108 Non-small-cell lung cancer 2C25.Y Phase 2 [17]
Ro 31-7453 DM83QCL Solid tumour/cancer 2A00-2F9Z Phase 2 [18]
P276-00 DM9DJL2 Mantle cell lymphoma 2A85.5 Phase 2 [17]
P-276 DMMJUHD Breast cancer 2C60-2C65 Phase 2 [19]
RGB-286638 DMEGOQP Haematological malignancy 2B33.Y Phase 1 [20]
AG-024322 DMY4WVK Solid tumour/cancer 2A00-2F9Z Phase 1 [17]
PHA-793887 DM2Y4FG Solid tumour/cancer 2A00-2F9Z Phase 1 [21]
Oxazolyl methylthiothiazole derivative 1 DMZM6FW N. A. N. A. Patented [14]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [22]
Roscovitine derivative 1 DMD1G3Z N. A. N. A. Patented [14]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Glycogen synthase kinase-3 beta (GSK-3B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AMO-02 DMJRU3A Myotonic dystrophy 8C71.0 Phase 2/3 [23]
LY2090314 DMTBFE4 Acute myeloid leukaemia 2A60 Phase 2 [4]
Lithium DMZ3OU6 Bipolar disorder 6A60 Phase 2 [24]
Tideglusib DME4LA1 Alzheimer disease 8A20 Phase 2 [25]
9-ING-41 DM57TY3 Myelofibrosis 2A20.2 Phase 2 [26]
Neu-120 DMXKOUC Parkinson disease 8A00.0 Phase 1/2 [27]
CHIR-99021 DMB8MNU Allergic inflammation 4A80-4A85 Patented [28]
TDZD-8 DMG6Q45 Malignant glioma 2A00.0 Patented [29]
AR-A014418 DMUPN01 Ovarian cancer 2C73 Patented [30]
PMID26161698-Compound-18 DM6JVR5 N. A. N. A. Patented [14]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Glycogen synthase kinase-3 alpha (GSK-3A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [31]
LY2090314 DMTBFE4 Acute myeloid leukaemia 2A60 Phase 2 [4]
Lithium DMZ3OU6 Bipolar disorder 6A60 Phase 2 [24]
CHIR-99021 DMB8MNU Allergic inflammation 4A80-4A85 Patented [4]
TDZD-8 DMG6Q45 Malignant glioma 2A00.0 Patented [4]
AR-A014418 DMUPN01 Ovarian cancer 2C73 Patented [4]
PMID27828716-Compound-21 DMO1NAR N. A. N. A. Patented [4]
Thiadiazolidindione derivative 2 DM5AUL0 N. A. N. A. Patented [4]
PMID27828716-Compound-18 DMNR6KL N. A. N. A. Patented [4]
PMID27828716-Compound-BIO-acetoxime DMUM5L6 Malignant glioma 2A00.0 Patented [4]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting G2/mitotic-specific cyclin B1 (CCNB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RO-316233 DMAGLPW Discovery agent N.A. Investigative [32]
Bisindolylmaleimide-I DMOQJZC Discovery agent N.A. Investigative [32]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 Discovery agent N.A. Investigative [33]
3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT Discovery agent N.A. Investigative [33]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY Discovery agent N.A. Investigative [33]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N Discovery agent N.A. Investigative [33]
AZAKENPAULLONE DM61H07 Discovery agent N.A. Investigative [3]
Thieno analogue of kenpaullone DMIOTHG Discovery agent N.A. Investigative [3]
3,4-bis(indol-3-yl)maleimide derivative DMEQ1HC Discovery agent N.A. Investigative [32]
4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine DMDW3SX Discovery agent N.A. Investigative [34]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Tyrosine-protein kinase Lck (LCK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [35]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [36]
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [37]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [38]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [39]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [40]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [41]
Enzalutamide DMGL19D Prostate cancer 2C82.0 Approved [42]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [43]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flupentixol DM0DJ9O Schizophrenia 6A20 Approved [45]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [46]
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [47]
Lamotrigine DM8SXYG Bipolar disorder 6A60 Approved [48]
Cepharanthine DM9Y5JB N. A. N. A. Approved [49]
Itraconazole DMCR1MV Aspergillosis 1F20 Approved [50]
Clozapine DMFC71L Schizophrenia 6A20 Approved [51]
Midostaurin DMI6E0R Acute myeloid leukaemia 2A60 Approved [52]
Trifluoperazine DMKBYWI Anxiety Approved [53]
Olanzapine DMPFN6Y Bipolar depression Approved [51]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Catenin beta-1 (CTNNB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [54]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [55]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [56]
Quercetin DM3NC4M Obesity 5B81 Approved [57]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [58]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [59]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [60]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [61]
Testosterone DM7HUNW Hot flushes GA30 Approved [62]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [63]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Transferrin receptor protein 2 (TFR2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [64]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [65]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [41]
Arsenic DMTL2Y1 N. A. N. A. Approved [66]
PEITC DMOMN31 Prostate cancer 2C82.0 Phase 2 [67]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [68]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [69]
Dorsomorphin DMKYXJW Discovery agent N.A. Investigative [8]
SU9516 DMQHG0R Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclin-dependent kinase 1 (CDK1) TTH6V3D CDK1_HUMAN Inhibitor [2]
Cyclin-dependent kinase 5 (CDK5) TTL4Q97 CDK5_HUMAN Inhibitor [3]
G2/mitotic-specific cyclin B1 (CCNB1) TT9P6OW CCNB1_HUMAN Inhibitor [2]
Glycogen synthase kinase-3 alpha (GSK-3A) TTRZQE3 GSK3A_HUMAN Inhibitor [4]
Glycogen synthase kinase-3 beta (GSK-3B) TTRSMW9 GSK3B_HUMAN Inhibitor [3]
Plasmodium CDK Pfmrk (Malaria Pfmrk) TTSFWA7 P90584_PLAFA Inhibitor [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Gene/Protein Processing [6]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Protein Interaction/Cellular Processes [7]
Transferrin receptor protein 2 (TFR2) OTMYCCEO TFR2_HUMAN Gene/Protein Processing [8]
Tyrosine-protein kinase Lck (LCK) OT883FG9 LCK_HUMAN Gene/Protein Processing [9]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6000).
2 Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur J Med Chem. 2010 Sep;45(9):4316-30.
3 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
4 Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
5 A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different class... J Med Chem. 2004 Oct 21;47(22):5418-26.
6 Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008 Aug;106(4):1855-65. doi: 10.1111/j.1471-4159.2008.05537.x. Epub 2008 Jul 4.
7 Proliferative and androgenic effects of indirubin derivatives in LNCaP human prostate cancer cells at sub-apoptotic concentrations. Chem Biol Interact. 2011 Feb 1;189(3):177-85. doi: 10.1016/j.cbi.2010.11.008. Epub 2010 Nov 25.
8 A HAMP promoter bioassay system for identifying chemical compounds that modulate hepcidin expression. Exp Hematol. 2015 May;43(5):404-413.e5. doi: 10.1016/j.exphem.2015.01.005. Epub 2015 Jan 26.
9 The specificities of protein kinase inhibitors: an update. Biochem J. 2003 Apr 1;371(Pt 1):199-204. doi: 10.1042/BJ20021535.
10 Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases, Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010).
11 Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1982-5.
12 Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10.
13 Evaluation of broad spectrum protein kinase inhibitors to probe the architecture of the malarial cyclin dependent protein kinase Pfmrk. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4961-6.
14 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
15 Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
16 Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36.
17 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
18 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
19 P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.
20 Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
21 A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
22 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
23 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
24 The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.
25 Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904.
26 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977.
27 Company report (Neurim Pharmaceuticals)
28 Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
29 Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3beta inhibitors through virtual screening. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7232-6.
30 Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71.
31 Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. Expert Opin Ther Targets. 2008 Nov;12(11):1367-76.
32 Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22.
33 Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
34 Synthesis and cytotoxic activity of 2-methylimidazo[1,2-a]pyridine- and quinoline-substituted 2-aminopyrimidine derivatives. Eur J Med Chem. 2010 Jan;45(1):379-86.
35 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
36 Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
37 Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011 Sep 22;54(18):6342-63. doi: 10.1021/jm2007613. Epub 2011 Aug 18.
38 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
39 Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
40 Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood. 2004 Aug 15;104(4):1094-9. doi: 10.1182/blood-2003-12-4266. Epub 2004 Apr 20.
41 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
42 LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
43 Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia. 2011 May;25(5):838-47. doi: 10.1038/leu.2011.2. Epub 2011 Feb 4.
44 Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells. Br J Pharmacol. 2013 May;169(1):167-78.
45 Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
46 Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
47 Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
48 Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
49 Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
50 Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
51 Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
52 Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
53 Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
54 Inhibition of autophagic flux differently modulates cannabidiol-induced death in 2D and 3D glioblastoma cell cultures. Sci Rep. 2020 Feb 14;10(1):2687. doi: 10.1038/s41598-020-59468-4.
55 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
56 Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol. 2008 Mar 31;583(1):26-31. doi: 10.1016/j.ejphar.2007.12.034. Epub 2008 Feb 5.
57 Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
58 Multifaceted suppression of aggressive behavior of thyroid carcinoma by all-trans retinoic acid induced re-differentiation. Mol Cell Endocrinol. 2012 Jan 2;348(1):260-9. doi: 10.1016/j.mce.2011.09.002. Epub 2011 Sep 6.
59 Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib. Leuk Res. 2008 Nov;32(11):1674-83. doi: 10.1016/j.leukres.2008.03.039. Epub 2008 May 15.
60 Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A. Oncogene. 2006 Oct 19;25(49):6447-56. doi: 10.1038/sj.onc.1209658. Epub 2006 Jul 31.
61 Benzene metabolite hydroquinone induces apoptosis of bone marrow mononuclear cells through inhibition of -catenin signaling. Toxicol In Vitro. 2018 Feb;46:361-369. doi: 10.1016/j.tiv.2017.08.018. Epub 2017 Sep 5.
62 Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways. Toxicol In Vitro. 2017 Apr;40:324-335. doi: 10.1016/j.tiv.2017.01.019. Epub 2017 Feb 2.
63 Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. Clin Cancer Res. 2017 Feb 1;23(3):789-803. doi: 10.1158/1078-0432.CCR-16-0226. Epub 2016 Aug 4.
64 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
65 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
66 Arsenic exposure from drinking water is associated with decreased gene expression and increased DNA methylation in peripheral blood. Toxicol Appl Pharmacol. 2017 Apr 15;321:57-66. doi: 10.1016/j.taap.2017.02.019. Epub 2017 Feb 24.
67 Phenethyl isothiocyanate alters the gene expression and the levels of protein associated with cell cycle regulation in human glioblastoma GBM 8401 cells. Environ Toxicol. 2017 Jan;32(1):176-187.
68 Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
69 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.